Moderna (NASDAQ:MRNA) will collaborate with Italian healthcare research group Chiesi Farmaceutici S.p.A. to discover and develop mRNA therapeutics for the treatment of pulmonary arterial hypertension (PAH), a rare disorder characterized by high blood pressure in the arteries of the lungs with concomitant right heart failure.
Under the terms of the agreement, Moderna will lead discovery while Chiesi Group will lead development and global commercialization. It will fund all expenses related to the partnership.
Moderna will receive $25M upfront, up to $400M in milestones and tiered double-digit royalties on net sales.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.